MPDL3280A Treatment in Patients With Locally Advance or Metastatic Non-small Cell Lung, Bladder and Triple Negative Breast Cancer After Investigational Imaging

Trial Profile

MPDL3280A Treatment in Patients With Locally Advance or Metastatic Non-small Cell Lung, Bladder and Triple Negative Breast Cancer After Investigational Imaging

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.
    • 09 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Feb 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top